Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kin...
Main Authors: | Bin Wang, Rui Li, Shuai Wu, Xin Liu, Jianlin Ren, Jing Li, Kaixin Bi, Yanhong Wang, Hongyan Jia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/full |
Similar Items
-
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
by: Ni Made Pitri Susanti, et al.
Published: (2021-07-01) -
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01) -
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
by: Lei Ding, et al.
Published: (2020-03-01) -
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
by: Paweł Łukasik, et al.
Published: (2021-03-01) -
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers
by: Rathos Maggie J, et al.
Published: (2012-08-01)